BioWa and Medarex Announce Expansion of Licensing Agreement

BioWa, Inc. and Medarex, Inc. announced that BioWa has granted a second license to Medarex to use BioWa's Potelligent Technology for the enhancement of antibody-dependent cellular cytotoxicity (ADCC). Medarex plans to use the Potelligent Technology to enhance the ADCC function of selected Medarex antibodies for potential therapeutic applications, including cancer. The agreement provides Medarex with nonexclusive commercial rights to develop antibodies for an undisclosed number of targets.

()a href="http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/05-24-2005/0003685104&EDATE=" target="_blank">PR Newswire